Cbinet.com Website Review

    > It was great to benchmark with other companies as well as walk away > with tangible and practical ideas.. > Director, Specialty Pharmacy Programs, BLUECROSS BLUESHIELD SOUTH > CAROLINA > CBI continues to deliver ‘Collaboration’ and ‘Best-In-Clas* > Interaction’ with our industry's finest.. Latest from the CBI Blog Q&A WITH EDWARD COX, CEO DTHERA™ SCIENCES. Edward Cox is CEO of Dthera™ Sciences, the leading digital thera*eutic company focusing on the elderly and individuals with neurodegenerative diseases, based in San Diego, CA. This summer they gained FDA breakthrough designation for their development-stage product, DTHR-ALZ for the symptoms of Alzheimer’s. We sat down with Ed to find out what this means and where he thinks things are headed for the rapidly advancing digital thera*eutic products sector. Q: What does receiving FDA breakthrough status mean for not just your company but the Digital Thera*eutic sector as a whole? CBI is the health and life sciences industry leader in providing thought leadership, actionable data, benchmarking, case studies and regulatory information through a dynamic conference platform that facilitates innovation, collaboration and elevation across the pharmaceutical, biotechnology, medical device and healthcare industries. CBI’s proprietary and intensive market research and product feasibility testing methodology has helped CBI deliver timely and first to market content driven conferences. These include annual Benefiting over 13,000 executives annually, CBI has provided the life sciences industry with leading-edge, actionable information on the most compelling industry trends for more than two decades. CBI’s conferences, forums, summits, workshops and other events also serve to connect executives and decision-makers with technology, regulatory and consulting solutions from Fortune 500 companies, and the most CBI’s DIR Fees Forum provides an excellent opportunity to learn more about what DIR Fees are used for and how they currently impact